NEW PUBLICATION: Exploring news media hype around gene therapy

A new editorial, published in the peer-reviewed open access journal Therapeutic Advances in Rare Disease (TAIRD), examines the potential effects of sensationalised news media coverage on haemophilia gene therapy.

Gene therapies have garnered significant public attention in recent years, with haemophilia being a prominent area of focus. However, such coverage often overlooks the complexities and benefit-risk trade-off of these treatments, leading to misconceptions about their true potential.

The editorial, co-authored by Laurence Woollard, MSc, Director of On The Pulse and Dr Richard Gorman, Assistant Professor in Ethics and Social Science at Brighton and Sussex Medical School, discusses how problematic language and framing in news media can perpetuate the idea of a “cure” for haemophilia. This may shape the perceptions of people living with haemophilia and their caregivers, influencing decisions in ways that may not align with the realities of treatment.

The piece stresses the importance of clear, responsible communication, calling for healthcare professionals, patient advocacy groups and gene therapy innovators to proactively manage expectations and promote informed decision-making (see Figure 1).

Illustration of a person living with haemophilia inside a floating bubble labelled “gene therapy hype”, surrounded by exaggerated news headlines. Outside the bubble, healthcare professionals and other stakeholders attempt to steady or deflate it, symbolising efforts to manage misinformation and expectations.
Figure 1. People living with haemophilia may find themselves caught in a ‘gene therapy hype’ bubble inflated by news media, highlighting the need for healthcare professionals and other stakeholders to mitigate the potential harms of disinformation and proactively manage expectations.

The full editorial provides a deeper look into these critical issues, which is available to access here.

This editorial builds on the authors’ previous work and advocacy in the advanced therapies space. For more, please see ‘Improving informed consent for gene therapy’.

Acknowledgements

The authors would like to acknowledge Samantha Taylor and Hemali Bedi at SAGE Publishing for their assistance throughout the publication process. Additionally, the authors would like to thank Lieke Bass and Dakota J. Rosenfelt for their contributions to the early ideation of this editorial.

Get in touch

For all work-related enquiries, please email Laurence at: [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *